SGLT2 inhibitors act from the extracellular surface of the cell membrane

Physiological Reports

Volumn 2, Issue 6, 2014, Pages

  Ghezzi, Chiara ^a   Hirayama, Bruce A ^a   Gorraitz, Edurne ^a   Loo, Donald D F ^a   Liang, Yin ^b   Wright, Ernest M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Inhibitors; SGLT2; Type II diabetes

Indexed keywords

ALPHA METHYLGLUCOSIDE; JNJ 30980924; PHLORIZIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TA 3404; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL MEMBRANE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ELECTROPHYSIOLOGY; EXTRACELLULAR MATRIX; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC50; NON INSULIN DEPENDENT DIABETES MELLITUS; SODIUM CURRENT; SUGAR TRANSPORT; WHOLE CELL PATCH CLAMP;

EID: 85003747891     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.12058     Document Type: Article

References (23)

1. Abdul-Ghani, M. A., L. Norton, and R. A. DeFronzo. 2012. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr. Diab. Rep. 2:230-238.
2. Chasis, H., N. Jolliffe, and H. W. Smith. 1933. The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man. J. Clin. Invest. 12:1083-1090.
3. Devineni, D., C. R. Curtin, D. Polidori, M. J. Gutierrez, J. Murphy, S. Rusch, et al. 2013. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J. Clin. Pharmacol. 53:601-610.
4. Eskandari, S., E. M. Wright, and D. D. Loo. 2005. Kinetics of the reverse mode of the Na+/glucose cotransporter. J. Membr. Biol. 204:23-32.
5. Ghezzi, C., and E. M. Wright. 2012. Regulation of the human Na+-dependent glucose cotransporter hSGLT2. Am. J. Physiol. Cell Physiol. 303:C348-C354.
6. Han, S., D. L. Hagan, J. R. Taylor, L. Xin, W. Meng, S. A. Biller, et al. 2008. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57:1723-1729.
7. Hirayama, B. A., M. P. Lostao, M. Panayotova-Heiermann, D. D. Loo, E. Turk, and E. M. Wright. 1996. Kinetic and specificity differences between rat, human, and rabbit Na+-glucose cotransporters (SGLT-1). Am. J. Physiol. 270: G919-G926.
8. Hummel, C. S., C. Lu, D. D. Loo, B. A. Hirayama, A. A. Voss, and E. M. Wright. 2011. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am. J. Physiol. Cell Physiol. 300:C14-C21.
9. Hummel, C. S., C. Lu, J. Liu, C. Ghezzi, B. A. Hirayama, D. D. F. Loo, et al. 2012. Structural selectivity of human SGLT inhibitors. Am. J. Physiol. Cell Physiol. 302:C373-C382.
10. Kasichayanula, S., X. Liu, F. Lacreta, S. C. Griffen, and D. W. Boulton. 2014. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin. Pharmacokinet. 53:17-27.
11. Koga, Y., S. Sakamaki, M. Hongu, E. Kawanishi, T. Sakamoto, Y. Yamamoto, et al. 2013. C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors. Bioorg. Med. Chem. 21:5561-5572.
12. Komoroski, B., N. Vachharajani, Y. Feng, L. Li, D. Kornhauser, and M. Pfister. 2009. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85:513-519.
13. Loo, D. D., B. A. Hirayama, M. Sala-Rabanal, and E. M. Wright. 2008. How drugs interact with transporters: SGLT1 as a model. J. Membr. Biol. 223:87-106.
14. Mamidi, R. N., F. Cuyckens, J. Chen, E. Scheers, D. Kalamaridis, R. Lin, et al. 2014. Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans. Drug Metab. Dispos. 42:903-916.
15. Nomura, S., S. Sakamaki, M. Hongu, E. Kawanishi, Y. Koga, T. Sakamoto, et al. 2010. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J. Med. Chem. 53:6355-6360.
16. Obermeier, M., M. Yao, A. Khanna, B. Koplowitz, M. Zhu, W. Li, et al. 2010. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab. Dispos. 38:405-414.
17. Rieg, T., T. Masuda, M. Gerasimova, E. Mayoux, K. Platt, D. R. Powell, et al. 2013. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am. J. Physiol. Renal. Physiol. 306:F188-F193.
18. Scheen, A. J. 2014. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin. Pharmacokinet. 53:213-225.
19. Seman, L., S. Macha, G. Nehmiz, G. Simons, B. Ren, S. Pinnetti, et al. 2013. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin. Pharmacol. Drug. Dev. 2:152-161.
20. Silverman, M. 1974. The in vivo localization of high-affinity phlorizin receptors to the brush border surface of the proximal tubule in dog kidney. Biochim. Biophys. Acta 339:92-102.
21. Umbach, J. A., M. J. Coady, and E. M. Wright. 1990. Intestinal Na+/glucose cotransporter expressed in Xenopus oocytes is electrogenic. Biophys. J. 57:1217-1224.
22. Vallon, V. S. K. 2010. Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Curr. Opin. Nephrol. Hypertens. 19:425-431.
23. Wright, E. M., D. D. Loo, and B. A. Hirayama. 2011. Biology of human sodium glucose transporters. Physiol. Rev. 91:733-794.